(VIANEWS) – SARTORIUS STED BIO (DIM.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| SARTORIUS STED BIO (DIM.PA) | €264.30 | 0.38% | 5.31% |
| VIRBAC (VIRP.PA) | €346.00 | 0.38% | 13.84% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. SARTORIUS STED BIO (DIM.PA)
0.38% Forward Dividend Yield and 5.31% Return On Equity
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.31%.
Yearly Top and Bottom Value
SARTORIUS STED BIO’s stock is valued at €264.30 at 22:30 EST, under its 52-week high of €281.00 and way above its 52-week low of €139.10.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 2, 2024, the estimated forward annual dividend rate is 0.69 and the estimated forward annual dividend yield is 0.38%.
Volume
Today’s last reported volume for SARTORIUS STED BIO is 48852 which is 29.49% below its average volume of 69287.
More news about SARTORIUS STED BIO.
2. VIRBAC (VIRP.PA)
0.38% Forward Dividend Yield and 13.84% Return On Equity
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Earnings Per Share
As for profitability, VIRBAC has a trailing twelve months EPS of €14.12.
PE Ratio
VIRBAC has a trailing twelve months price to earnings ratio of 24.5. Meaning, the purchaser of the share is investing €24.5 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.84%.
Yearly Top and Bottom Value
VIRBAC’s stock is valued at €346.00 at 22:30 EST, under its 52-week high of €377.50 and way higher than its 52-week low of €239.00.
Moving Average
VIRBAC’s worth is above its 50-day moving average of €344.94 and higher than its 200-day moving average of €342.65.
Volatility
VIRBAC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.07%, a negative 0.18%, and a positive 1.66%.
VIRBAC’s highest amplitude of average volatility was 1.71% (last week), 1.45% (last month), and 1.66% (last quarter).
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 25, 2024, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 0.38%.
More news about VIRBAC.
